Pharmacokinetics of Non-Intravenous Formulations of Fentanyl

@article{Ltsch2013PharmacokineticsON,
  title={Pharmacokinetics of Non-Intravenous Formulations of Fentanyl},
  author={J{\"o}rn L{\"o}tsch and Carmen Walter and Michael John Dr Parnham and Bruno Georg Oertel and Gerd Geisslinger},
  journal={Clinical Pharmacokinetics},
  year={2013},
  volume={52},
  pages={23-36}
}
Fentanyl was structurally designed by Paul Janssen in the early 1960s as a potent opioid analgesic (100-fold more potent than morphine). It is a full agonist at μ-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol:water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7–6.6 min). It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability ~30… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic

  • Front. Psychiatry
  • 2018
VIEW 16 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats.

  • Toxicological sciences : an official journal of the Society of Toxicology
  • 2018
VIEW 2 EXCERPTS
CITES BACKGROUND